LINE

    Text:AAAPrint
    Sci-tech

    Domestic antiviral drug promising

    1
    2022-05-19 10:01:39China Daily Editor : Li Yan ECNS App Download
    Special: Battle Against Novel Coronavirus

    A Chinese drug for treating patients infected by the Omicron variant has shown good results in terms of drug safety, tolerability and effectiveness in reducing viral shedding, or the amount of time that infected cells release reproduced viruses.

    According to Huashan Ganran, the official WeChat account run by the National Medical Center for Infectious Diseases and the infectious diseases department at Huashan Hospital affiliated with Fudan University, the drug VV116 is able to inhibit the replication of coronavirus variants including Omicron.

    A Phase 1 clinical trial held from March 8 to 24 involved 136 hospitalized COVID-19 patients divided into a treatment group of 60 patients who received VV116 in addition to standard treatment and a control group of 76 patients who didn't take the drug.

    According to an announcement on Wednesday on the WeChat account, the Phase 1 clinical trial suggested that the viral shedding time was cut to 8.56 days in the treatment group, in contrast with 11.13 days in the control group.

    It worked the same on symptomatic patients who took the drug within two to 10 days of their first positive nucleic acid test. No serious side effects have occurred so far.

    The study was a collaborative effort by the National Medical Center for Infectious Diseases; Shanghai Key Lab of Infectious Diseases and Biosafety Emergency Response; a Shanghai medical team from Huashan hospital led by infectious disease expert Zhang Wenhong; a team from Shanghai Public Health Clinical Center led by Fan Xiaohong; and a lab at Shanghai Lingang special area in Pudong New Area.

    However, due to the limited sample size and none of the participants being critical or severe COVID-19 patients, it's still unknown if the drug could prevent patients from progressing from mild to critical illness, the research team said.

    The study, An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants, was published in the journal Emerging Microbes and Infections on Wednesday.

    MorePhoto

    Most popular in 24h

    MoreTop news

    MoreVideo

    LINE
    Back to top About Us | Jobs | Contact Us | Privacy Policy
    Copyright ©1999-2022 Chinanews.com. All rights reserved.
    Reproduction in whole or in part without permission is prohibited.
    [網上傳播視聽節目許可證(0106168)] [京ICP證040655號]
    [京公網安備 11010202009201號] [京ICP備05004340號-1]
    主站蜘蛛池模板: 泾源县| 额尔古纳市| 岫岩| 句容市| 泸水县| 永泰县| 朝阳市| 皋兰县| 含山县| 馆陶县| 清远市| 大宁县| 溧水县| 双峰县| 樟树市| 张家港市| 沁水县| 哈密市| 武宁县| 三明市| 临汾市| 咸阳市| 民县| 大同县| 大新县| 福清市| 开阳县| 仙居县| 英德市| 张家口市| 青岛市| 都兰县| 瓦房店市| 周至县| 玉环县| 临江市| 宝应县| 惠安县| 海林市| 福建省| 饶阳县|